10-Q · May 13, 2026
Omeros Corporation's Q1 2026 10-Q report shows a strong financial position, primarily driven by the launch of YARTEMLEA, which generated $9.9 million in revenue during its first reporting period. The company also posted…
Earnings analysis · 10-Q
OMER earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
Q2 2026 showed strong commercial momentum, with YARTEMLEA net revenue rising to $28.5 million from $9.9 million in Q1 and operating cash flow turning positive at $4.1 million. Liquidity was $132.0 million at June 30,…
Read full summary
Q2 2026 showed strong commercial momentum, with YARTEMLEA net revenue rising to $28.5 million from $9.9 million in Q1 and operating cash flow turning positive at $4.1 million. Liquidity was $132.0 million at June 30, 2026, but the period also included a $60.2 million debt-repurchase cash outlay and an $11.5 million non-cash gain that limits the quality of reported earnings. The negative European CHMP opinion on narsoplimab and sensitivity of the 2029 Notes derivative to stock-price movements remain significant risks, while no numeric financial guidance was provided.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Segment
- YARTEMLEA net revenue: $28.5 million, compared with $9.9 million in Q1 2026; other segment revenue was not disclosed in the provided filing text.
What stood out
-
YARTEMLEA revenue accelerated
YARTEMLEA net revenue increased to $28.5 million from $9.9 million in Q1 2026, indicating strong sequential commercial-launch momentum.
-
Operations generated positive cash
Operating cash flow was positive at $4.1 million in Q2 2026, an improvement from negative operating cash flow in the prior periods referenced in the earnings materials.
-
Liquidity remained substantial
Cash, cash equivalents and short-term investments totaled $132.0 million as of June 30, 2026, providing liquidity to fund operations.
-
Share repurchases continued
The company repurchased 488,716 shares during Q2 at an average price of $11.70 per share; approximately $90.1 million remained available under the $100.0 million program as of August 12, 2026.
-
Controls remained effective
Management concluded disclosure controls were effective at the reasonable-assurance level as of June 30, 2026, with no material change in internal control over financial reporting during the quarter.
What to watch
-
European regulatory setback
The negative CHMP opinion on narsoplimab in Europe represents a regulatory setback and could constrain the product's potential European commercialization opportunity; the filing materials identify the European regulatory outcome as a material headwind.
-
Derivative valuation volatility
A 20% increase or decrease in the company's stock price would produce an approximately $15.8 million change in the fair value of the 2029 Notes embedded derivative; the derivative's reported fair value ranged from $40.4 million to $71.0 million under the stated valuation range.
-
Repurchase program risk
The share repurchase program may increase stock-price volatility and can be suspended or terminated at any time; approximately $90.1 million remained available for repurchases as of August 12, 2026.
-
Large debt-repurchase cash outlay
The $60.2 million cash cost associated with debt repurchases reduced liquidity despite positive operating cash flow of $4.1 million in Q2 2026.
-
Profit benefited from non-cash gain
Reported earnings benefited from an $11.5 million non-cash gain, reducing the quality and sustainability of the quarter's reported profit.
Management's outlook
No numeric revenue or EPS guidance was provided. Management expects enrollment to begin in two YARTEMLEA studies by year-end 2026 and targets an OMS805 Phase 1b trial in late 2027.
Earlier filings 4
10-K · March 31, 2026
Omeros Corporation reported a significant turnaround in Q4 2025, highlighting the FDA approval of YARTEMLEA and a substantial sale of zaltenibart to Novo Nordisk, resulting in a net income boost. Although revenue…
10-Q · November 13, 2025
Omeros Corporation reported no revenue for Q3 2025, while its diluted EPS of -0.34 exceeded expectations of -0.52. Notably, the company anticipates receiving $240 million from a transaction with Novo Nordisk to bolster…
10-Q · August 14, 2025
Omeros Corporation's Q2 2025 results exhibited continued setbacks, including a reported EPS of -0.43 against a consensus estimate of -0.55, with no revenue reported for the quarter. The company is navigating through…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.